• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Te­va hands Cell­tri­on $160M to grab US rights on two biosim­i­lars of Roche block­busters

9 years ago
R&D
Pharma

Pi­lot project pro­vides a snap­shot of ef­fec­tive­ness of Pfiz­er’s PARP con­tender ta­la­zoparib

9 years ago
R&D

Feds help NewLink, Mer­ck out with some added cash for Ebo­la vac­cine

9 years ago
R&D
Pharma

Al­ny­lam shares crater af­ter tri­al deaths force in­ves­ti­ga­tors to scrap PhI­II RNAi drug

9 years ago
R&D

Can We Con­quer All Dis­eases By The End Of The Cen­tu­ry? An In­ter­view with Chan Zucker­berg's Cori Bargmann.

9 years ago
People

UK start­up tack­les hot neoanti­gen field in can­cer drugs

9 years ago
Financing
Startups

Biotech bil­lion­aire backs a food al­ler­gy/nu­tri­tion start­up; Ed­i­tas re­cruits a CMO

9 years ago
News Briefing

An­dré Chouli­ka on gene edit­ing: "If you mar­ry your­self to a tech­nol­o­gy, you're doomed."

9 years ago
People

As­traZeneca jet­ti­sons an­oth­er drug, this time grab­bing $30M for out-li­cens­ing deal

9 years ago
R&D

Hold the ap­plause: Big Phar­ma has lit­tle to brag about re­gard­ing 2016 R&D pro­duc­tiv­i­ty

9 years ago
R&D
Pharma

No­var­tis un­veils a new glob­al R&D struc­ture, cre­at­ing cen­ters in Cam­bridge, MA and Basel

9 years ago
R&D
Pharma

No­var­tis is up­root­ing an­oth­er re­search group in on­go­ing glob­al re­or­ga­ni­za­tion

9 years ago
R&D
Pharma

Sam­sung BioEpis pitch­es Her­ceptin biosim­i­lar as par­ent com­pa­ny hunts $2B IPO; Chi­as­ma CEO is out

9 years ago
News Briefing

Hus­tling to cap­ture top front­line NSCLC sta­tus, Roche scores a ‘break­through’ on Ale­cen­sa

9 years ago
R&D

Am­gen joins a mar­quee list of part­ners jump­ing on Nuevo­lu­tion’s dis­cov­ery plat­form

9 years ago
R&D
Pharma

To­bi­ra chair­man’s din­ner with Brent: In­dus­try chat led to a 3-month pur­suit and a stun­ning $1.7B deal

9 years ago
Deals

So­ri­ot’s $3.5B Bril­in­ta dream is dashed by yet an­oth­er big tri­al flop for As­traZeneca

9 years ago
R&D

Sum­mit shares rock­et up, fu­eled by an $842M pact with Duchenne leader Sarep­ta

9 years ago
R&D

Ko­re­an of­fi­cials launch Han­mi probe in wake of tox re­ports; Prothena CEO Schenk dies

9 years ago
News Briefing

Sun Phar­ma takes aim at a crowd­ed mar­ket with an­oth­er IL-23 pso­ri­a­sis drug from Mer­ck

9 years ago
R&D

Mer­ri­mack CEO is out as the biotech re­struc­tures, chop­ping its work­force and over­haul­ing R&D

9 years ago
R&D
Pharma

$95M mega-round in hand, Elaine Sul­li­van sets out to build a Eu­ro­pean on­col­o­gy play­er

9 years ago
R&D

As­traZeneca hands off an­oth­er Am­gen-part­nered drug in a $1.5B deal with an ac­quis­i­tive Al­ler­gan

9 years ago
R&D
Pharma

Presto! Wall Street ma­gi­cian Vivek Ra­maswamy has an­oth­er in­stant biotech IPO to sell you

9 years ago
People
Financing
First page Previous page 1153115411551156115711581159 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.